Radiology

Dr. Scott D. Flamm, Former Section Head of Cardiovascular Imaging at Cleveland Clinic, Joins DocPanel

Retrieved on: 
Monday, May 1, 2023
San Francisco, Cardiac imaging, CT, Cleveland Clinic, Society, University, European Heart Journal: Cardiovascular Imaging, American Heart Association, American College of Cardiology, Head, Heart, University of California, San Francisco Fetal Treatment Center, FACC, Burlo Garofolo Pediatric Institute, MBA, Kellogg School, Radiology, MRI, Adrian Dixon, FAHA, Scientific Computing and Imaging Institute, Knowledge, American College, Northwestern University, Society for Cardiovascular Magnetic Resonance, Medical device

Formerly with Cleveland Clinic, Dr. Flamm served as Head of Cardiovascular Imaging with joint appointments in the Imaging Institute, Heart, Vascular, and Thoracic Institute, and the Pediatric Institute (2006-2023).

Key Points: 
  • Formerly with Cleveland Clinic, Dr. Flamm served as Head of Cardiovascular Imaging with joint appointments in the Imaging Institute, Heart, Vascular, and Thoracic Institute, and the Pediatric Institute (2006-2023).
  • "DocPanel and I share a mutual mission to make subspecialized cardiac imaging routine care that can be accessed by all," says Dr. Flamm.
  • Through the DocPanel platform, healthcare facilities can access Dr. Flamm for dedicated cardiothoracic imaging coverage, protocol assistance, and program development support.
  • Dr. Flamm completed fellowship training in Cardiovascular Imaging and MRI at the University of California San Francisco under Dr. Charles Higgins.

RadNet’s Quantib B.V. Subsidiary Receives FDA Clearance for its Quantib Prostate™ 3.0 Software

Retrieved on: 
Monday, May 1, 2023
Federal Food, Drug, and Cosmetic Act, Communication, Workflow, Prostate, Movement, Radiology, MRI, Urology, Physician, Diagnosis, FDA, PSA, Prostate cancer, Software, Medical device, AI

Quantib Prostate™ software for MRI reading support was first introduced in the US, followed by a class IIb CE marking in Europe in 2021.

Key Points: 
  • Quantib Prostate™ software for MRI reading support was first introduced in the US, followed by a class IIb CE marking in Europe in 2021.
  • Quantib Prostate™ 3.0 is a state-of-the-art AI-based software solution that advances the MRI prostate reporting workflow and its output for radiologists and urologists.
  • The FDA 510k special clearance introduces a major upgrade to the latest Quantib Prostate 2.1 release.
  • We strive to regularly and continuously improve our software in order to support radiologists and urologists in the best possible way,” said Arthur Post Uiterweer, CEO of Quantib.

bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer

Retrieved on: 
Monday, May 1, 2023
Research, Radiology, Pharmaceutical, Oncology, Medical Devices, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Russell Investments, Certified Public Accountant, American Institute of Certified Public Accountants, BIAF, Lung, Human voice, Amazon, Diagnosis, Financial management, American Institute, Idera, Inc., Management

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced that Michael Dougherty has joined the company as Chief Financial Officer, effective today.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced that Michael Dougherty has joined the company as Chief Financial Officer, effective today.
  • Mr. Dougherty will report directly to bioAffinity Technologies President and Chief Executive Officer Maria Zannes.
  • Previously, Mr. Dougherty was Chief Financial and Operating Officer of TINT, a user-generated content platform, and Chief Financial Officer at Filestack, a secure file handling service provider that was acquired by Idera, Inc.
  • Prior to that, Mr. Dougherty served as Chief Financial Officer for Amazon Pay, where he supported Amazon’s digital payment wallet globally.

Run Rich Run: 40 Yards Closer to Helping 400,000 Kids Around the World, St. Jude Patient Runs 4.7 second 40-Yard-Dash to Benefit St. Jude Children’s Research Hospital

Retrieved on: 
Saturday, April 29, 2023
Women, Stem Cells, Other Philanthropy, Sports, Managed Care, Men, Family, Surgery, Consumer, Radiology, Oncology, Children, Entertainment, Baby, Maternity, Hospitals, Celebrity, Football, Philanthropy, Health, Fund Raising, Foundation, Fanconi anemia, Survival rate, NFL, Travel, Housing, Food, University, University of Michigan, Kidney cancer, NCI-designated Cancer Center, ALSAC, League, St. Jude Children's Research Hospital, Cancer, Eye, NFL Network, Hope, Wilms' tumor, National Cancer Institute (Egypt), Multimedia, Athlete, National Cancer Institute, Dream, Patient, Super Bowl, Child, Love, Motivation, National Football League Draft, Hospital, Leukemia, Rhabdomyosarcoma, DSM-IV codes, Jude the Apostle

Joining him were St. Jude patients and NFL ambassadors supporting the lifesaving mission of St. Jude: Finding cures.

Key Points: 
  • Joining him were St. Jude patients and NFL ambassadors supporting the lifesaving mission of St. Jude: Finding cures.
  • View the full release here: https://www.businesswire.com/news/home/20230429005038/en/
    Emmy-nominated NFL Network host Rich Eisen suited up and sprinted for St. Jude Children’s Research Hospital® this week during his annual Run Rich Run event.
  • Joining him were St. Jude patients and NFL ambassadors supporting the lifesaving mission of St. Jude: Finding cures.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Retrieved on: 
Saturday, April 29, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, DRS, Positron emission tomography, SNMMI, Prostate cancer, Diarrhea, PSMA, AUA, ASTRO, PET, Multimedia, RH, Prostate, Radiopharmaceutical, Response evaluation criteria in solid tumors, ASCO, Hypertension, Injection site reaction, Recurrence, Physician, Division, American Urological Association, NorthShore University HealthSystem, Prostate-specific antigen, Headache, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, PSA, Food, Medical imaging, MD, Patient, Urology

18F-rhPSMA-7.3 is an investigational high affinity radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted PET imaging agent.

Key Points: 
  • 18F-rhPSMA-7.3 is an investigational high affinity radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted PET imaging agent.
  • The results were reported in a moderated poster presentation at the American Urological Association’s 2023 Annual Meeting (AUA2023), in Chicago, Ill.
  • “The utility of conventional imaging for the localization of recurrence is limited, and relapse after curative-intent radiation therapy remains a considerable clinical burden.
  • These findings from the Phase 3 SPOTLIGHT subgroup study showed high detection rates by majority read for 18F-rhPSMA-7.3 across all regions.

ENDRA Life Sciences Announces Pricing of Upsized $4.5 Million Public Offering

Retrieved on: 
Friday, April 28, 2023
Health, Medical Devices, Hospitals, Other Science, Radiology, Science, Biotechnology, Telephone, Enterprise file synchronization and sharing, Securities and Exchange Commission (Nigeria), Sale, Suite, NDRA, ATTN:, Security (finance)

ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced an underwritten public offering of 3,750,000 shares of its common stock and warrants to purchase 1,875,000 shares of its common stock.

Key Points: 
  • ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced an underwritten public offering of 3,750,000 shares of its common stock and warrants to purchase 1,875,000 shares of its common stock.
  • All of the securities in the underwritten public offering were sold by ENDRA.
  • The Company has granted the underwriter a 30-day option to purchase additional shares of common stock and warrants to purchase shares of its common stock sold in the offering solely to cover over-allotments.
  • The common stock and warrants to purchase common stock described above were offered by ENDRA pursuant to a registration statement (File No.

Global AI-Enabled Medical Imaging Solutions Market Research Report 2023: An $18.356 Billion Market by 2032, Growing at a CAGR of 25.76% - ResearchAndMarkets.com

Retrieved on: 
Friday, April 28, 2023
Health, Radiology, Technology, Health Technology, Artificial Intelligence, Workflow, Frontiers, Deep learning, COVID-19, Prognosis, Machine learning, Systematic review, Artificial intelligence, Drug discovery, Growth, Diagnosis, Region, AI, Country, Medical device, Pharmaceutical industry

The global AI-enabled medical imaging solutions market was valued at $1,854.5 million in 2022 and is anticipated to reach $18,356.5 million by 2032, witnessing a CAGR of 25.76% during the forecast period 2022-2032.

Key Points: 
  • The global AI-enabled medical imaging solutions market was valued at $1,854.5 million in 2022 and is anticipated to reach $18,356.5 million by 2032, witnessing a CAGR of 25.76% during the forecast period 2022-2032.
  • The AI-enabled medical imaging solutions market is in the developing phase.
  • AI-enabled medical imaging solutions in emerging countries, technological advancements in imaging devices, and the adoption of artificial intelligence and deep learning in imaging systems are some of the major opportunities in the global AI-enabled medical imaging solutions market.
  • Key players in the global AI-enabled medical imaging solutions market analyzed and profiled in the study involve players that offer AI-enabled medical imaging solutions.

Chandana Lall, M.D., M.B.A., to join City of Hope as chair of diagnostic radiology and vice dean of clinical faculty affairs

Retrieved on: 
Friday, April 28, 2023
Maimonides Medical Center, City of Hope National Medical Center, American College of Radiology, City of Hope, University, Society, Health, Medical imaging, Faculty of Management Studies – University of Delhi, Cancer, Business, Research, Abdominal Radiology, Radiology, Mount Sinai Beth Israel, Radiological Society of North America, Science, Lall, American Board of Commissioners for Foreign Missions, City, Magnetic resonance imaging, Boswell, Knowledge, American College, University of California, Irvine Medical Center, Recurrence, Hope

LOS ANGELES, April 28, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States, has announced Chandana "Sandy" Lall, M.D., M.B.A., will join the organization as chair of Diagnostic Radiology and vice dean of clinical faculty affairs, effective July 1, 2023.

Key Points: 
  • LOS ANGELES, April 28, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States, has announced Chandana "Sandy" Lall, M.D., M.B.A., will join the organization as chair of Diagnostic Radiology and vice dean of clinical faculty affairs, effective July 1, 2023.
  • Lall currently serves as chair and professor of the radiology department at the University of Florida Jacksonville, and previously served as vice chair and professor of radiology and urology at the University of California Irvine.
  • "It is a great honor to join City of Hope's world-class diagnostic radiology department," said Lall.
  • "I look forward to partnering with my colleagues to integrate the most sophisticated imaging technologies into City of Hope's clinical trials and cancer therapies.

INSIGHTEC CHAIRMAN OF THE BOARD AND CEO, MAURICE R. FERRÉ TO PRESENT AT 2023 MILKEN INSTITUTE GLOBAL CONFERENCE

Retrieved on: 
Friday, April 28, 2023
Focused Ultrasound Foundation, University, Therapy, University of Michigan, Stanford University, Disease, DSM-IV codes, Driving Towards the Daylight, Policy, Innovation system, ALS, PST, Biomedical engineering, Doctor of Philosophy, The Drive, Glioblastoma, Government, Associate, Essential tremor, BBB, Parkinson's disease, MD, Patient, Artificial intelligence, Growth, LOS, Alzheimer's disease, Health, The Beverly Hilton, Conference, Music, Chase Koch, Medical device, Radiology

LOS ANGELES, April 28, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using focused ultrasound technology to transform patient care, today announced that Maurice R. Ferré MD, the Chairman of the Board of Directors and CEO, will be a featured speaker at the 2023 Milken Institute Global Conference in Los Angeles, California on Monday, May 1, 2023 at 11:30 a.m. PST.  

Key Points: 
  • Dr. Maurice Ferré to join more than 900 leaders in business, government, philanthropy, health, and entertainment for four-day event focused on "Advancing a Thriving World"
    LOS ANGELES, April 28, 2023 /PRNewswire/ -- Insightec , a global healthcare company dedicated to using focused ultrasound technology to transform patient care, today announced that Maurice R. Ferré MD, the Chairman of the Board of Directors and CEO, will be a featured speaker at the 2023 Milken Institute Global Conference in Los Angeles, California on Monday, May 1, 2023 at 11:30 a.m. PST.
  • Dr. Ferré will join a panel discussion entitled, "The Drive Toward More Non-Invasive Treatments for Patients" to discuss recent advancements in focused ultrasound technology for the treatment of essential tremor , Parkinson's disease and other movement disorders.
  • Additionally, Dr. Ferré will highlight on-going clinical trials where focused ultrasound is combined with novel therapeutics for delivery across the blood brain barrier (BBB) in patients with glioblastoma, metastatic lung cancer, Alzheimer's Disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis.
  • The conference will run April 30 - May 3 at The Beverly Hilton in Los Angeles, CA.

2023 IOF International Orthodontic Symposium: Register for Cutting-Edge Insights & Innovations

Retrieved on: 
Thursday, April 27, 2023
Partnership, Autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndrome, University, Cleft lip and cleft palate, Obstructive sleep apnea, HKU, IOF, Research, Palate, Radiology, Orthodontics, Patient, Knowledge, FOD, Tutoring, Dentistry, Future

The 2023 IOF International Orthodontic Symposium is scheduled to take place from June 16 to 18 in vibrant Hong Kong, China.

Key Points: 
  • The 2023 IOF International Orthodontic Symposium is scheduled to take place from June 16 to 18 in vibrant Hong Kong, China.
  • They will deliver captivating lectures and panel discussions in five sessions, sharing their insights, experiences, and cutting-edge technology.
  • The International Orthodontic Foundation (IOF) and The University of Hong Kong Faculty of Dentistry (HKU FoD) will be co-organizing the symposium.
  • This is an opportunity not to be missed for anyone looking to expand their knowledge and take their orthodontic skills to the next level.